1. Academic Background Glioblastoma (GBM) and pediatric diffuse midline gliomas (e.g., H3K27M-mutant) are among the most aggressive tumors of the central nervous system (CNS), with limited efficacy from conventional treatments (surgery, radiotherapy, chemotherapy). For decades, the CNS was considered to have “immune privilege,” meaning the immune s...

Study on Connexin43-Mediated Temozolomide Resistance in Glioma through Activation of the E2F1/ERCC1 Axis Academic Background Glioma is the most common and fatal tumor of the central nervous system, with temozolomide (TMZ) being the standard treatment. However, TMZ therapy often leads to tumor recurrence and drug resistance, severely limiting its ef...

Background Introduction Glioma is one of the most common primary tumors of the central nervous system, and its prognosis and treatment methods vary significantly depending on molecular characteristics. In recent years, with the advancement of molecular pathology, IDH (isocitrate dehydrogenase) mutations have been identified as important molecular m...

Immunogenicity and Therapeutic Challenges of IDH-Mutant Gliomas Background Glioma is a common central nervous system tumor, and its treatment and prognosis vary significantly depending on molecular characteristics. In recent years, the diagnostic and prognostic significance of isocitrate dehydrogenase (IDH) mutations in gliomas has been increasingl...

Induction of Tertiary Lymphoid Structures in Glioma Immunotherapy and Their Anti-Tumor Immune Effects Background Introduction Glioma is a highly malignant brain tumor characterized by limited lymphocyte infiltration in the tumor microenvironment (glioma microenvironment, GME), presenting an “immune desert” state. This characteristic makes glioma in...